Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bhagat, Neelakshi, M.D., M.P.H.
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Age 18 years or over

• Subjects with diabetes mellitus

• Subjects with proliferative diabetic retinopathy induced rubeosis

• Be willing to undergo cataract surgery

• HgbA1c level < 12%

Exclusion Criteria:

• History of glaucoma surgery

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis

• Intraocular surgery in the study eye within 60 days preceding Day 0

• History of prior pars plana vitrectomy in the study eye

• Positive pregnancy test

• HbA1c >12